-logo-1200x675.png?v=20220915161652&w=240&h=240&zc=2){kind=logo}
Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded by StockNews.com to Buy
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday. Separately, Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday. Read Our Latest Report […]
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday. Separately, Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday. Read Our Latest Report […]
